Drugs Containing Excipient (Inactive Ingredient) PEG-54 HYDROGENATED CASTOR OIL

Generic drugs containing PEG-54 HYDROGENATED CASTOR OIL excipient

Company	Ingredient	NDC	Excipient
Rhodes Pharmaceuticals LP	lidocaine and prilocaine	42858-029	PEG-54 HYDROGENATED CASTOR OIL
Alembic Pharmaceuticals Limited	lidocaine and prilocaine	46708-582	PEG-54 HYDROGENATED CASTOR OIL
Alembic Pharmaceuticals Inc	lidocaine and prilocaine	62332-582	PEG-54 HYDROGENATED CASTOR OIL
Aleor Dermaceuticals Limited	lidocaine and prilocaine	71589-017	PEG-54 HYDROGENATED CASTOR OIL

PEG-54 Hydrogenated Castor Oil: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

PEG-54 Hydrogenated Castor Oil, a widely utilized pharmaceutical excipient, demonstrates consistent demand driven by its multifaceted applications in drug formulation. Its market trajectory is characterized by stable growth, influenced by the expanding pharmaceutical industry, regulatory landscapes, and evolving drug delivery technologies.

What are the Primary Applications of PEG-54 Hydrogenated Castor Oil in Pharmaceuticals?

PEG-54 Hydrogenated Castor Oil serves as a crucial component in a diverse range of pharmaceutical dosage forms. Its amphiphilic nature, stemming from the hydrophilic polyethylene glycol (PEG) chain and the lipophilic hydrogenated castor oil base, enables it to function effectively as a solubilizer, emulsifier, and stabilizer [1].

• Solubilization of Poorly Soluble Drugs: A significant application involves enhancing the solubility of hydrophobic active pharmaceutical ingredients (APIs). This is critical for oral, parenteral, and topical formulations, where API solubility directly impacts bioavailability and efficacy. For instance, in solid oral dosage forms, it can be incorporated into solid dispersions or granules to improve dissolution rates [2].
• Emulsification: It acts as an emulsifying agent in the creation of stable oil-in-water and water-in-oil emulsions. These are commonly found in topical creams, lotions, and certain injectable formulations. Its ability to reduce interfacial tension between oil and water phases is key to achieving homogeneous and stable emulsion systems [3].
• Drug Delivery Systems: PEG-54 Hydrogenated Castor Oil is integral to the development of advanced drug delivery systems. This includes its use in:
  • Microemulsions and Nanoemulsions: These systems offer enhanced drug loading capacity and improved permeation across biological barriers, particularly for poorly soluble drugs and for transdermal delivery [4].
  • Self-Emulsifying Drug Delivery Systems (SEDDS) and Self-Microemulsifying Drug Delivery Systems (SMEDDS): These formulations are designed to spontaneously form fine oil-in-water emulsions or microemulsions upon contact with aqueous media in the gastrointestinal tract, thereby improving oral bioavailability of lipophilic drugs [5].
  • Controlled Release Formulations: It can be used to modify the release profile of APIs, contributing to sustained or targeted drug delivery.

What are the Key Market Drivers for PEG-54 Hydrogenated Castor Oil?

The market for PEG-54 Hydrogenated Castor Oil is primarily driven by the global expansion of the pharmaceutical industry and the increasing prevalence of chronic diseases requiring advanced therapeutic interventions.

• Growth in the Pharmaceutical Industry: The global pharmaceutical market, projected to reach over $1.7 trillion by 2025, fuels the demand for excipients like PEG-54 Hydrogenated Castor Oil [6]. Increased drug development and manufacturing activities directly translate to higher consumption of this excipient.
• Rise in Biologics and Complex Drug Modalities: The burgeoning field of biologics and the development of complex drug molecules, many of which exhibit poor aqueous solubility, necessitate advanced formulation strategies. Excipients that facilitate solubilization and enhance bioavailability are in high demand [7].
• Increasing Demand for Oral Drug Delivery: Oral administration remains the preferred route of drug delivery due to patient convenience and compliance. Formulations designed for improved oral absorption of poorly soluble drugs, where PEG-54 Hydrogenated Castor Oil plays a vital role, are therefore a significant market driver [5].
• Advancements in Drug Delivery Technologies: The continuous innovation in drug delivery systems, including nanotechnology and personalized medicine approaches, requires sophisticated excipients. PEG-54 Hydrogenated Castor Oil's versatility makes it adaptable to these evolving technologies [4].
• Regulatory Support for Quality Excipients: Stringent regulatory requirements by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate the use of high-purity, well-characterized excipients. Manufacturers of PEG-54 Hydrogenated Castor Oil that meet these standards benefit from increased market access [8].

What are the Major Market Restraints and Challenges?

Despite robust growth, the PEG-54 Hydrogenated Castor Oil market faces certain restraints.

• Availability and Cost of Raw Materials: The price and consistent availability of hydrogenated castor oil and polyethylene glycol, the primary raw materials, can influence production costs and, consequently, the market price of the final excipient. Fluctuations in agricultural commodity markets can indirectly impact supply chains [9].
• Development of Alternative Excipients: Ongoing research and development in the pharmaceutical excipient space may lead to the emergence of novel, potentially more effective or cost-efficient alternatives. While PEG-54 Hydrogenated Castor Oil has established performance profiles, continuous innovation from competitors poses a challenge [10].
• Regulatory Hurdles for Novel Formulations: While regulatory bodies support quality excipients, the approval process for novel drug formulations utilizing specialized excipients can be lengthy and complex, potentially delaying market entry and adoption [8].
• Concerns Regarding PEGylated Compounds: In certain therapeutic areas, there have been discussions and research into potential immunogenic responses to PEGylated compounds. While PEG-54 Hydrogenated Castor Oil's structure is distinct from some intravenously administered PEGylated drugs, it remains an area of ongoing scientific scrutiny that could influence future adoption in sensitive applications [11].

What is the Current Market Size and Projected Growth for PEG-54 Hydrogenated Castor Oil?

The market for pharmaceutical excipients, within which PEG-54 Hydrogenated Castor Oil is a component, is substantial and exhibits steady growth. While specific market size data for PEG-54 Hydrogenated Castor Oil alone is not consistently granular, it contributes to the broader polyoxyethylene alkyl ethers and castor oil derivatives market segments.

• Excipients Market Growth: The global pharmaceutical excipients market was valued at approximately $9.9 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2030, reaching an estimated $15.6 billion by 2030 [12]. PEG-54 Hydrogenated Castor Oil is expected to track this overall market trend, driven by its widespread use.
• Contribution to Specific Segments: Within the broader excipients market, PEG-54 Hydrogenated Castor Oil falls under categories such as solubilizers, emulsifiers, and functional excipients for advanced drug delivery. These segments are experiencing robust demand due to the increasing number of poorly soluble APIs entering clinical development.
• Projected Growth Rate: Based on the factors driving its application, the demand for PEG-54 Hydrogenated Castor Oil is anticipated to experience a CAGR in the range of 5-7% over the next five to seven years, mirroring the growth of specialized excipients used in complex formulations.

Who are the Key Players in the PEG-54 Hydrogenated Castor Oil Market?

The market for PEG-54 Hydrogenated Castor Oil is characterized by a mix of large chemical manufacturers and specialized excipient suppliers. Competition is driven by product quality, regulatory compliance, supply chain reliability, and technical support.

Key manufacturers and suppliers include:

• BASF SE: A global leader in specialty chemicals, offering a wide range of pharmaceutical excipients, including ethoxylated castor oil derivatives.
• Croda International Plc: Known for its expertise in oleochemicals and specialty ingredients, Croda provides castor oil derivatives and PEG-based excipients.
• Kao Corporation: A Japanese chemical company with a significant presence in oleochemicals, supplying ingredients for pharmaceutical and cosmetic applications.
• Solvay S.A.: A Belgian multinational chemical company with a diverse portfolio, including excipients for the pharmaceutical industry.
• Ashland Global Holdings Inc.: A global specialty materials company that offers a range of pharmaceutical excipients for various drug delivery applications.
• Other Regional Suppliers: Numerous smaller and regional players contribute to the market, particularly in Asia-Pacific, catering to local pharmaceutical manufacturers.

What are the Regulatory Considerations for PEG-54 Hydrogenated Castor Oil?

The use of PEG-54 Hydrogenated Castor Oil in pharmaceutical products is governed by strict regulatory guidelines to ensure patient safety and product efficacy. Compliance with pharmacopoeial standards and good manufacturing practices (GMP) is paramount.

• Pharmacopoeial Standards: PEG-54 Hydrogenated Castor Oil must comply with monographs in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs specify purity requirements, identification tests, assay limits, and limits for impurities (e.g., residual solvents, heavy metals) [13].
• Regulatory Filings: Manufacturers must provide detailed information about the excipient, including its manufacturing process, quality control measures, and stability data, as part of drug product regulatory submissions (e.g., New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs)).
• GMP Compliance: Manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) to ensure consistent quality and safety of the excipient. This includes robust quality management systems, validated processes, and thorough documentation [14].
• REACH and Other Chemical Regulations: As a chemical substance, PEG-54 Hydrogenated Castor Oil is subject to chemical registration and evaluation regulations in various regions, such as REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) in the European Union. Manufacturers must ensure compliance with these broad chemical safety regulations [15].
• Impurities and Degradation Products: Regulators pay close attention to potential impurities or degradation products arising from the excipient, as these can impact the safety and efficacy of the final drug product. Stability studies are crucial to identify and quantify any such substances under various storage conditions.

What is the Financial Trajectory and Investment Outlook?

The financial trajectory for PEG-54 Hydrogenated Castor Oil is one of predictable, steady growth, directly linked to the expanding pharmaceutical industry and the increasing need for sophisticated drug delivery solutions. Investment in this segment is generally considered low to moderate risk, with stable returns.

• Revenue Streams: Revenue generation for manufacturers of PEG-54 Hydrogenated Castor Oil is derived from bulk sales to pharmaceutical companies and contract manufacturing organizations (CMOs). Pricing is influenced by raw material costs, production volume, product quality, and regulatory compliance.
• Profitability: Profit margins are typically stable, influenced by economies of scale in production and efficient supply chain management. Companies with strong IP protection for novel formulations utilizing the excipient may command premium pricing.
• Investment Opportunities:
  • Manufacturing Expansion: Investment in expanding production capacity to meet growing demand is a common strategy. This requires capital expenditure for new facilities or upgrades to existing ones, coupled with adherence to strict quality and regulatory standards.
  • Research and Development: Companies investing in R&D to explore new applications or synergistic combinations of PEG-54 Hydrogenated Castor Oil with other excipients for novel drug delivery systems can create significant market differentiation and future revenue growth.
  • Mergers and Acquisitions: Consolidation within the pharmaceutical excipient market is ongoing. Acquisitions of smaller, specialized players by larger chemical conglomerates or excipient suppliers can represent strategic investment opportunities, particularly those with strong regulatory track records and niche product portfolios.
• Market Trends Influencing Investment: The increasing focus on oral bioavailability enhancement, the development of biologics, and the demand for personalized medicine are key trends that support continued investment in excipients like PEG-54 Hydrogenated Castor Oil. Investors seeking exposure to the pharmaceutical supply chain with a focus on stable growth are likely to find this segment attractive.

Key Takeaways

PEG-54 Hydrogenated Castor Oil is a fundamental pharmaceutical excipient with a robust market driven by its solubilizing and emulsifying properties. Its demand is directly correlated with the growth of the global pharmaceutical industry and the increasing development of complex drug molecules requiring advanced delivery systems. The market is characterized by stable growth, with projections aligning with the overall pharmaceutical excipients sector CAGR of approximately 5.9%. Key players include major chemical and specialty ingredient manufacturers. Regulatory compliance with pharmacopoeial standards and GMP is critical. The financial trajectory is stable, offering opportunities in manufacturing expansion and R&D for novel applications, making it a reliable segment within the pharmaceutical supply chain.

FAQs

1. What is the typical purity standard for pharmaceutical-grade PEG-54 Hydrogenated Castor Oil? Pharmaceutical-grade PEG-54 Hydrogenated Castor Oil must meet stringent purity requirements as defined by major pharmacopoeias such as USP, Ph. Eur., and JP. These typically include limits on heavy metals, residual solvents, and specific impurities.

2. Are there any known safety concerns associated with PEG-54 Hydrogenated Castor Oil in pharmaceutical formulations? PEG-54 Hydrogenated Castor Oil is generally recognized as safe (GRAS) for its intended use as a pharmaceutical excipient when manufactured and used according to regulatory guidelines. Its safety profile is well-established for various routes of administration.

3. How does PEG-54 Hydrogenated Castor Oil differ from other hydrogenated castor oil derivatives? The primary difference lies in the length of the polyethylene glycol (PEG) chain attached to the hydrogenated castor oil molecule. The "54" in PEG-54 indicates the average number of ethylene oxide units in the PEG chain, which dictates its hydrophilic-lipophilic balance (HLB) and thus its specific functional properties as a solubilizer or emulsifier.

4. Can PEG-54 Hydrogenated Castor Oil be used in pediatric formulations? Yes, PEG-54 Hydrogenated Castor Oil can be used in pediatric formulations, provided it meets all relevant pharmacopoeial and regulatory requirements for such sensitive applications and its safety is confirmed through formulation-specific evaluations.

5. What are the primary raw materials for the synthesis of PEG-54 Hydrogenated Castor Oil? The primary raw materials are hydrogenated castor oil, which is derived from castor oil, and ethylene oxide, which is used to create the polyethylene glycol chain through ethoxylation.

Citations

[1] Charman, W. N. (2006). Enhanced Intestinal Absorption of Drugs. Biotechnology and Genetic Engineering Reviews, 23(1), 327–343.

[2] Singh, S., Sharma, R., Sharma, V., & Goyal, R. (2022). Solid Dispersions for Enhancing the Oral Bioavailability of Poorly Water-Soluble Drugs. In Advanced Pharmaceutical Processes (pp. 207-232). Springer.

[3] Ghosh, S., Singh, V., & Singh, R. (2015). Role of Excipients in Emulsion Formulation. International Journal of Pharmaceutical Sciences and Research, 6(6), 2338-2350.

[4] Khan, S., et al. (2019). Nanoemulsions for Advanced Drug Delivery. In Nanotechnology-Based Approaches for Drug Delivery (pp. 1-30). Springer.

[5] Kumar, R., & Singh, G. (2021). Self-Emulsifying Drug Delivery Systems: Formulation and Evaluation. Journal of Drug Delivery, 2021, 1-10.

[6] Grand View Research. (2023). Pharmaceutical Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030.

[7] Llinás, A., & van der Wal, S. (2017). Formulation challenges for biologics. Drug Discovery Today, 22(9), 1337-1345.

[8] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from https://www.fda.gov/

[9] MarketsandMarkets. (2022). Pharmaceutical Excipients Market.

[10] Momin, M. A. (2020). Novel Excipients for Pharmaceutical Formulations. Pharma Times, 52(5), 35-40.

[11] Jølck, A. C., et al. (2020). PEGylation of therapeutic proteins: challenges and opportunities. Expert Opinion on Biological Therapy, 20(8), 933-944.

[12] Mordor Intelligence. (2023). Pharmaceutical Excipients Market – Growth, Trends, COVID-19 Impact, and Forecasts (2023 – 2028).

[13] United States Pharmacopeial Convention. (2023). United States Pharmacopeia – National Formulary.

[14] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/

[15] European Chemicals Agency. (n.d.). REACH. Retrieved from https://echa.europa.eu/